Pharming PHAR Stock
Pharming Price Chart
Pharming PHAR Financial and Trading Overview
| Pharming stock price | 11.9 USD |
| Previous Close | 10.6 USD |
| Open | 11.32 USD |
| Bid | 17.34 USD x 100 |
| Ask | 12.17 USD x 100 |
| Day's Range | 10.76 - 11.45 USD |
| 52 Week Range | 9.11 - 21.34 USD |
| Volume | 25.78K USD |
| Avg. Volume | 23.94K USD |
| Market Cap | 792.72M USD |
| Beta (5Y Monthly) | 0.074 |
| PE Ratio (TTM) | 86.15385 |
| EPS (TTM) | 0.13 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.35 USD |
PHAR Valuation Measures
| Enterprise Value | 747.73M USD |
| Trailing P/E | 86.15385 |
| Forward P/E | 29.09091 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.163057 |
| Price/Book (mrq) | 2.9319372 |
| Enterprise Value/Revenue | 2.04 |
| Enterprise Value/EBITDA | 22.742 |
Trading Information
Pharming Stock Price History
| Beta (5Y Monthly) | 0.074 |
| 52-Week Change | -15.97% |
| S&P500 52-Week Change | 10.88% |
| 52 Week High | 21.34 USD |
| 52 Week Low | 9.11 USD |
| 50-Day Moving Average | 10.68 USD |
| 200-Day Moving Average | 13.94 USD |
PHAR Share Statistics
| Avg. Volume (3 month) | 23.94K USD |
| Avg. Daily Volume (10-Days) | 13.46K USD |
| Shares Outstanding | 70.78M |
| Float | 69.66M |
| Short Ratio | 0.57 |
| % Held by Insiders | 0% |
| % Held by Institutions | 0.13% |
| Shares Short | 20.1K |
| Short % of Float | 0.029% |
| Short % of Shares Outstanding | 0.029% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 2.53% |
| Operating Margin (ttm) | 1.45% |
| Gross Margin | 86.52% |
| EBITDA Margin | 8.97% |
Management Effectiveness
| Return on Assets (ttm) | 3.46% |
| Return on Equity (ttm) | 3.64% |
Income Statement
| Revenue (ttm) | 366.48M USD |
| Revenue Per Share (ttm) | 5.22 USD |
| Quarterly Revenue Growth (yoy) | -3.20% |
| Gross Profit (ttm) | 317.08M USD |
| EBITDA | 32.88M USD |
| Net Income Avi to Common (ttm) | 9.3M USD |
| Diluted EPS (ttm) | 0.13 |
| Quarterly Earnings Growth (yoy) | -65.10% |
Balance Sheet
| Total Cash (mrq) | 158.28M USD |
| Total Cash Per Share (mrq) | 2.24 USD |
| Total Debt (mrq) | 113.3M USD |
| Total Debt/Equity (mrq) | 41.89 USD |
| Current Ratio (mrq) | 3.01 |
| Book Value Per Share (mrq) | 3.82 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 35.03M USD |
| Levered Free Cash Flow (ttm) | 37.69M USD |
Profile of Pharming
| Country | United States |
| State | N/A |
| City | Leiden |
| Address | Darwinweg 24 |
| ZIP | 2333 CR |
| Phone | 31 71 524 7400 |
| Website | https://www.pharming.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 407 |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Q&A For Pharming Stock
What is a current PHAR stock price?
Pharming PHAR stock price today per share is 11.9 USD.
How to purchase Pharming stock?
You can buy PHAR shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pharming?
The stock symbol or ticker of Pharming is PHAR.
Which industry does the Pharming company belong to?
The Pharming industry is Biotechnology.
How many shares does Pharming have in circulation?
The max supply of Pharming shares is 70.78M.
What is Pharming Price to Earnings Ratio (PE Ratio)?
Pharming PE Ratio is 91.53846000 now.
What was Pharming earnings per share over the trailing 12 months (TTM)?
Pharming EPS is 0.13 USD over the trailing 12 months.
Which sector does the Pharming company belong to?
The Pharming sector is Healthcare.
Pharming PHAR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26169.38 USD — |
+0.82
|
6.51B USD — | 25986.56 USD — | 26306.82 USD — | — - | 6.51B USD — |
|
US Tech Global Market Composite
NQGM
US
|
1986.69 USD — |
+0.34
|
— — | 1975.47 USD — | 2002.03 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1333.33 USD — |
+0.41
|
— — | 1325.41 USD — | 1341.7 USD — | — - | — — |
- {{ link.label }} {{link}}
